Raymond James Financial Inc. Takes Position in Haemonetics Co. (NYSE:HAE)

Raymond James Financial Inc. purchased a new stake in Haemonetics Co. (NYSE:HAE) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 243,364 shares of the medical instruments supplier’s stock, valued at approximately $19,002,000. Raymond James Financial Inc. owned about 0.48% of Haemonetics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Parkside Financial Bank & Trust lifted its stake in shares of Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after buying an additional 240 shares during the period. KBC Group NV lifted its stake in shares of Haemonetics by 54.6% in the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock valued at $157,000 after buying an additional 712 shares during the period. iSAM Funds UK Ltd bought a new stake in shares of Haemonetics in the third quarter valued at about $204,000. Empowered Funds LLC bought a new stake in shares of Haemonetics in the fourth quarter valued at about $319,000. Finally, Captrust Financial Advisors lifted its stake in shares of Haemonetics by 30.1% in the third quarter. Captrust Financial Advisors now owns 4,248 shares of the medical instruments supplier’s stock valued at $341,000 after buying an additional 982 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Stock Performance

NYSE:HAE opened at $65.76 on Monday. Haemonetics Co. has a 1 year low of $58.80 and a 1 year high of $97.97. The firm has a 50 day moving average of $68.61 and a 200-day moving average of $75.41. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The stock has a market capitalization of $3.30 billion, a P/E ratio of 25.89, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, sell-side analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Raymond James reiterated a “strong-buy” rating and issued a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Needham & Company LLC cut their price target on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Barrington Research cut their price target on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. Finally, JMP Securities cut their price target on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $101.67.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.